Business Context and Reporting Period
This Form 8-K was filed by Allegiant Travel Company on April 20, 2020. The report details the entry into a Payroll Support Program Agreement (PSPA) with the U.S. Department of the Treasury under the CARES Act to support operations during the COVID-19 pandemic.
Key Financial Metrics and Agreements
- Total PSPA Award: Approximately $171.9 million expected allocation.
- Initial Grant Received: $86.0 million (restricted for wages, salaries, and benefits).
- Debt Obligation: Upon full funding, the company will issue a senior unsecured term promissory note of approximately $21.6 million at a low-interest rate, maturing 10 years after issuance.
- Equity Obligation: Upon full funding, the company will issue warrants to purchase 25,898 shares of common stock at $83.33 per share, expiring five years after issuance.
- Additional Liquidity Application: The company has applied for a CARES Act Loan Program in the principal amount of approximately $276 million, with funds expected to be available through September 30, 2020.
Material Changes and Restrictions
The filing introduces significant new financial obligations and operational restrictions tied to the CARES Act funding:
- Capital Restrictions: Prohibition on repurchasing common stock and paying common stock dividends until September 30, 2021.
- Compensation Restrictions: Limits on certain executive compensation payments through March 24, 2022.
- Loan Program Restrictions: If the additional $276 million loan is secured, similar restrictions on stock buybacks, dividends, and executive compensation will apply until one year after the loan is repaid.
Outlook, Risks, and Contingencies
Management expects to complete mutually agreeable terms for the additional loan program, though this is subject to Treasury approval. The filing includes forward-looking statements regarding future funding and the impact of the COVID-19 pandemic. Key risks include the severity and duration of business disruption caused by the pandemic, which could cause actual results to differ materially from expectations.
Investor Verification Checklist
- Confirm the final funding status of the $171.9 million PSPA award and the issuance of the $21.6 million promissory note.
- Verify the approval status and terms of the additional $276 million CARES Act Loan Program application.
- Monitor compliance with the dividend and stock repurchase moratoriums extending through September 2021.
- Review the impact of executive compensation restrictions on management retention and incentives through 2022.
- Assess the ongoing operational impact of the COVID-19 pandemic on revenue and liquidity beyond the support provided by the CARES Act.